Han-shen P. Tae

Wollongong, NSW 2522, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Isodrimenine Derivatives Selectively Inhibit Human α7-Containing Nicotinic Acetylcholine Receptors via Negative Allosteric Modulation.

Isodrimenine Derivatives Selectively Inhibit Human α7-Containing Nicotinic Acetylcholine Receptors via Negative Allosteric Modulation.

Journal: ACS chemical neuroscience

Published: December 17, 2025

Dual Agonist/Antagonist Modulation of α9-Containing Nicotinic Acetylcholine Receptors by 2-Ammoniumethyl Ethers of Stilbenol and Stilbenol Analogues.

Dual Agonist/Antagonist Modulation of α9-Containing Nicotinic Acetylcholine Receptors by 2-Ammoniumethyl Ethers of Stilbenol and Stilbenol Analogues.

Journal: Journal of medicinal chemistry

Published: December 08, 2025

Dual-Action Tetrapeptide Analogue of Psychrophilic Fungal Origin: Potent Inhibitor of Human Nicotinic Acetylcholine Receptors with Antinociceptive and Muscle-Relaxant Activity.

Dual-Action Tetrapeptide Analogue of Psychrophilic Fungal Origin: Potent Inhibitor of Human Nicotinic Acetylcholine Receptors with Antinociceptive and Muscle-Relaxant Activity.

Journal: Journal of medicinal chemistry

Published: December 03, 2025

A deep learning framework (CreoPep) for target-specific design and optimization of conotoxin peptides.

A deep learning framework (CreoPep) for target-specific design and optimization of conotoxin peptides.

Journal: Communications chemistry

Published: August 25, 2025

Erabutoxin mutants demonstrate interface selectivity at human fetal and adult muscle-type nicotinic acetylcholine receptors.

Erabutoxin mutants demonstrate interface selectivity at human fetal and adult muscle-type nicotinic acetylcholine receptors.

Journal: Biochemical pharmacology

Published: March 31, 2025

Functional and structural interactions of novel acrylamide-based compounds with the α7 nicotinic acetylcholine receptor.

Functional and structural interactions of novel acrylamide-based compounds with the α7 nicotinic acetylcholine receptor.

Journal: Biochemical pharmacology

Published: March 25, 2025

Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain.

Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain.

Journal: Journal of medicinal chemistry

Published: October 24, 2024

N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor.

N-Terminal Capping of the αO-Conotoxin Analogue GeX-2 Improves the Serum Stability and Selectivity toward the Human α9α10 Nicotinic Acetylcholine Receptor.

Journal: Journal of medicinal chemistry

Published: October 03, 2024

Molecular determinants of the selectivity and potency of α-conotoxin Vc1.1 for human nicotinic acetylcholine receptors.

Molecular determinants of the selectivity and potency of α-conotoxin Vc1.1 for human nicotinic acetylcholine receptors.

Journal: The Journal of biological chemistry

Published: September 03, 2024

Dual Antagonism of α9α10 nAChR and GABAB Receptor-Coupled CaV2.2 Channels by an Analgesic αO-Conotoxin Analogue.

Dual Antagonism of α9α10 nAChR and GABAB Receptor-Coupled CaV2.2 Channels by an Analgesic αO-Conotoxin Analogue.

Journal: Journal of medicinal chemistry

Published: January 13, 2024

Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine Receptors.

Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine Receptors.

Journal: Marine drugs

Published: December 22, 2023

Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel.

Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel.

Journal: Biochemical pharmacology

Published: December 06, 2023

Showing 1-12 of 55

Last Updated: 09/26/2026